#METABOLOMICS WORKBENCH AnthonyDon_20250929_182902 DATATRACK_ID:6506 STUDY_ID:ST004262 ANALYSIS_ID:AN007092 PROJECT_ID:PR002689
VERSION             	1
CREATED_ON             	October 5, 2025, 12:46 am
#PROJECT
PR:PROJECT_TITLE                 	Histone methyltransferase PRDM9 promotes survival of drug-tolerant persister
PR:PROJECT_TITLE                 	cells in glioblastoma
PR:PROJECT_SUMMARY               	Chemotherapy often kills a large fraction of cancer cells but leaves behind a
PR:PROJECT_SUMMARY               	small population of drug tolerant persister cells. These persister cells survive
PR:PROJECT_SUMMARY               	drug treatments through reversible, non-genetic mechanisms and cause tumour
PR:PROJECT_SUMMARY               	recurrence upon cessation of therapy. Here, we report a drug tolerance mechanism
PR:PROJECT_SUMMARY               	regulated by the germ-cell-specific H3K4 methyltransferase PRDM9. Through
PR:PROJECT_SUMMARY               	histone proteomic, transcriptomic, lipidomic, and ChIP-sequencing studies
PR:PROJECT_SUMMARY               	combined with CRISPR knockout and phenotypic drug screen, we identified that
PR:PROJECT_SUMMARY               	chemotherapy-induced PRDM9 upregulation promotes metabolic rewiring in
PR:PROJECT_SUMMARY               	glioblastoma stem cells, leading to chemotherapy tolerance. Mechanistically,
PR:PROJECT_SUMMARY               	PRDM9-dependent H3K4me3 at cholesterol biosynthesis genes enhances cholesterol
PR:PROJECT_SUMMARY               	biosynthesis, which persister cells rely on to maintain homeostasis under
PR:PROJECT_SUMMARY               	chemotherapy induced oxidative stress and lipid peroxidation. PRDM9 inhibition,
PR:PROJECT_SUMMARY               	combined with chemotherapy, resulted in strong anti-cancer efficacy in
PR:PROJECT_SUMMARY               	preclinical glioblastoma models, significantly enhancing the magnitude and
PR:PROJECT_SUMMARY               	duration of the antitumor response by eliminating persisters. These findings
PR:PROJECT_SUMMARY               	demonstrate a previously unknown role of PRDM9 in promoting metabolic
PR:PROJECT_SUMMARY               	reprogramming that enables the survival of drug-tolerant persister cells.
PR:INSTITUTE                     	The University of Sydney
PR:DEPARTMENT                    	School of Medical Sciences
PR:LAST_NAME                     	Don
PR:FIRST_NAME                    	Anthony
PR:ADDRESS                       	Office 3210, D17 Charles Perkins Centre, Camperdown, NSW, 2006, Australia
PR:EMAIL                         	anthony.don@sydney.edu.au
PR:PHONE                         	+612 8627 5578
PR:PUBLICATIONS                  	Histone methyltransferase PRDM9 promotes survival of drug-tolerant persister
PR:PUBLICATIONS                  	cells in glioblastoma
#STUDY
ST:STUDY_TITLE                   	The lipidome of drug-resistant glioblastoma persister cells.
ST:STUDY_SUMMARY                 	This study aimed to determine mechanisms through which glioblastoma stem cells
ST:STUDY_SUMMARY                 	acquire a drug-resistant phenotype. A small proportion of glioblastoma stem
ST:STUDY_SUMMARY                 	cells survive chemotherapy and radiotherapy, creating a drug-resistant persister
ST:STUDY_SUMMARY                 	cell population that resumes proliferation after the cessation of drug
ST:STUDY_SUMMARY                 	treatment. The specific experiment profiled the lipidome of glioblastoma stem
ST:STUDY_SUMMARY                 	cells that survive treatment with the anti-microtubule agent CMPD1. Glioblastoma
ST:STUDY_SUMMARY                 	stem cell line RKI1 was treated for 14 days with 25 micromolar CMPD1 to generate
ST:STUDY_SUMMARY                 	drug-resistant persister cells, replacing the cell culture medium every 3 days
ST:STUDY_SUMMARY                 	(n = 3). At day 14 of treatment, the CMPD1-treated cells were collected for
ST:STUDY_SUMMARY                 	lipid extraction and lipidomic analysis. The drug-resistant persister cells were
ST:STUDY_SUMMARY                 	compared to control cells grown in RKI1 growth medium and collected prior to
ST:STUDY_SUMMARY                 	drug-treatment (n = 3). The drug-resistant persister cells displayed
ST:STUDY_SUMMARY                 	significantly decreased levels of ceramide and cholesterol, and increased
ST:STUDY_SUMMARY                 	sphingomyelin and diacylgylcerol, indicative of membrane remodelling that may
ST:STUDY_SUMMARY                 	allow the cells to survive chemotherapy. Further investigation indicated that
ST:STUDY_SUMMARY                 	the reduced cholesterol content provides a point of metabolic vulnerability to
ST:STUDY_SUMMARY                 	eliminate the drug resistant persister cells.
ST:INSTITUTE                     	University of Sydney
ST:DEPARTMENT                    	School of Medical Sciences
ST:LAST_NAME                     	Don
ST:FIRST_NAME                    	Anthony
ST:ADDRESS                       	Office 3210, D17 Charles Perkins Centre, Camperdown, NSW, 2006
ST:EMAIL                         	anthony.don@sydney.edu.au
ST:PHONE                         	+612 8627 5578
ST:NUM_GROUPS                    	2
ST:TOTAL_SUBJECTS                	6
ST:STUDY_COMMENTS                	Control and drug-treated RKI1 glioblastoma cells
ST:PUBLICATIONS                  	Histone methyltransferase PRDM9 promotes survival of drug-tolerant persister
ST:PUBLICATIONS                  	cells in glioblastoma
#SUBJECT
SU:SUBJECT_TYPE                  	Cultured cells
SU:SUBJECT_SPECIES               	Homo sapiens
SU:TAXONOMY_ID                   	9606
SU:CELL_BIOSOURCE_OR_SUPPLIER    	QIMR Berghofer Institute
SU:CELL_STRAIN_DETAILS           	Patient-derived glioblastoma stem cell line RKI1
#SUBJECT_SAMPLE_FACTORS:         	SUBJECT(optional)[tab]SAMPLE[tab]FACTORS(NAME:VALUE pairs separated by |)[tab]Raw file names and additional sample data
SUBJECT_SAMPLE_FACTORS           	-	4	Sample source:RKI1 cells | Factor:Control	RAW_FILE_NAME(Raw file name)=4
SUBJECT_SAMPLE_FACTORS           	-	5	Sample source:RKI1 cells | Factor:Control	RAW_FILE_NAME(Raw file name)=5
SUBJECT_SAMPLE_FACTORS           	-	3	Sample source:RKI1 cells | Factor:Control	RAW_FILE_NAME(Raw file name)=3
SUBJECT_SAMPLE_FACTORS           	-	1	Sample source:RKI1 cells | Factor:Drug Treated	RAW_FILE_NAME(Raw file name)=1
SUBJECT_SAMPLE_FACTORS           	-	6	Sample source:RKI1 cells | Factor:Drug Treated	RAW_FILE_NAME(Raw file name)=6
SUBJECT_SAMPLE_FACTORS           	-	2	Sample source:RKI1 cells | Factor:Drug Treated	RAW_FILE_NAME(Raw file name)=2
#COLLECTION
CO:COLLECTION_SUMMARY            	Glioblastoma stem cell line RKI1 is a patient-derived line described in:
CO:COLLECTION_SUMMARY            	Stringer BW, et al. A reference collection of patient-derived cell line and
CO:COLLECTION_SUMMARY            	xenograft models of proneural, classical and mesenchymal glioblastoma.
CO:COLLECTION_SUMMARY            	Scientific Reports 9, 4902 (2019). These cells are available at:
CO:COLLECTION_SUMMARY            	https://www.qimrberghofer.edu.au/our-research/commercialisation/q-cell/. RKI1
CO:COLLECTION_SUMMARY            	cells are cultured in KnockOut DMEM/F-12 basal medium kit with neural
CO:COLLECTION_SUMMARY            	supplement, EGF (20 ng/mL) and FGF-β (10 ng/mL) (ThermoFisher Scientific, Cat#
CO:COLLECTION_SUMMARY            	579 A1050901). GlutaMAX-ICTS (2 mM) (Thermofisher Scientific, Cat# A1286001) and
CO:COLLECTION_SUMMARY            	Antibiotic- Antimycotic (Thermofisher Scientific, Cat# 15240112) were also
CO:COLLECTION_SUMMARY            	added. Adherent cells were plated on flasks coated with 0.15% in PBS MatriGel
CO:COLLECTION_SUMMARY            	Matrix (Corning Life Sciences, Cat# BDAA356237), incubated at 37 °C, 5% CO2.
CO:COLLECTION_SUMMARY            	Specific treatment conditions are described under "treatment".
CO:SAMPLE_TYPE                   	Glioma cells
#TREATMENT
TR:TREATMENT_SUMMARY             	RKI1 cells (1.5 × 10^4 cells/cm2) were grown in 10 cm2 dishes and treated with
TR:TREATMENT_SUMMARY             	CMPD1 (25 μM) for 14 days. Every 3 days, the media containing CMPD1 was
TR:TREATMENT_SUMMARY             	replaced. At Day 14, three independent cultures of drug tolerant persister (DTP)
TR:TREATMENT_SUMMARY             	cells were collected for lipidomic analysis. Control cells were RKI1 cells grown
TR:TREATMENT_SUMMARY             	in culture medium without CMPD1 (1.5 x 10^5 cells in 10 cm2 dishes). Three
TR:TREATMENT_SUMMARY             	independent cultures of the cells were used. RKI1 cells are cultured in KnockOut
TR:TREATMENT_SUMMARY             	DMEM/F-12 basal medium kit with neural supplement, EGF (20 ng/mL) and FGF-β (10
TR:TREATMENT_SUMMARY             	ng/mL) (ThermoFisher Scientific, Cat# 579 A1050901). GlutaMAX-ICTS (2 mM)
TR:TREATMENT_SUMMARY             	(Thermofisher Scientific, Cat# A1286001) and Antibiotic- Antimycotic
TR:TREATMENT_SUMMARY             	(Thermofisher Scientific, Cat# 15240112) were also added. Adherent cells were
TR:TREATMENT_SUMMARY             	plated on flasks coated with 0.15% in PBS MatriGel Matrix (Corning Life
TR:TREATMENT_SUMMARY             	Sciences, Cat# BDAA356237), incubated at 37 °C, 5% CO2.
#SAMPLEPREP
SP:SAMPLEPREP_SUMMARY            	RKI1 parent and CMPD1-derived drug-tolerant persister cells were collected,
SP:SAMPLEPREP_SUMMARY            	homogenized in sample extraction buffer (50 mM Hepes pH 7.4, 25 mM KCl, Protease
SP:SAMPLEPREP_SUMMARY            	Inhibitor Cocktail) by sonicating for 5 min (30 s on/30 s off) at 4ºC with a
SP:SAMPLEPREP_SUMMARY            	Qsonica Q800R2 sonicating bath. Protein concentration was determined with the
SP:SAMPLEPREP_SUMMARY            	BCA assay. Lipids were extracted from 200 µL lysate (~200 µg protein) using
SP:SAMPLEPREP_SUMMARY            	the methyl-tert-butyl ether (MTBE)/methanol/water protocol. Cell homogenate was
SP:SAMPLEPREP_SUMMARY            	combined with 250 µL methanol containing 0.01%
SP:SAMPLEPREP_SUMMARY            	3,5-di-tert-4-butylhydroxyltoluene (BHT), internal standards and 850 µL MTBE,
SP:SAMPLEPREP_SUMMARY            	sonicated in a 4°C water bath for 30 min, and phase separation was induced by
SP:SAMPLEPREP_SUMMARY            	centrifuging at 2000g for 5 min. The upper organic phase was transferred to a 5
SP:SAMPLEPREP_SUMMARY            	mL glass tube, and the aqueous phase was re-extracted with 500 µL MTBE and 150
SP:SAMPLEPREP_SUMMARY            	µL methanol. The organic phase from the second extraction was combined with the
SP:SAMPLEPREP_SUMMARY            	first, after which the extracts were dried in a Savant SC210 SpeedVac dessicator
SP:SAMPLEPREP_SUMMARY            	(ThermoFisher Scientific). Lipids were reconstituted in 400 µL of 80% (v/v)
SP:SAMPLEPREP_SUMMARY            	methanol:20% water containing 0.01% BHT, 1 mM ammonium formate, and 0.1% formic
SP:SAMPLEPREP_SUMMARY            	acid, and stored at -80 degrees C.
#CHROMATOGRAPHY
CH:CHROMATOGRAPHY_TYPE           	Reversed phase
CH:INSTRUMENT_NAME               	Thermo Vanquish
CH:COLUMN_NAME                   	Waters ACQUITY UPLC CSH C18 (100 x 2.1mm,1.7um)
CH:SOLVENT_A                     	10 mM ammonium formate, 0.1% formic acid, 60% acetonitrile and 40% water
CH:SOLVENT_B                     	10 mM ammonium formate, 0.1% formic acid, 10% acetonitrile and 90% isopropanol
CH:FLOW_GRADIENT                 	0-3 min, 20% B; 3-5.5 min, ramp to 45% B; 5.5-8 min, ramp to 65% B; 8-13 min,
CH:FLOW_GRADIENT                 	ramp to 85% B; 13-14 min, ramp to 100% B; 14-20 min, hold at 100% B; 20-25 min,
CH:FLOW_GRADIENT                 	decrease to 20% B and hold to 25 min
CH:FLOW_RATE                     	0.28 ml/min
CH:COLUMN_TEMPERATURE            	45
#ANALYSIS
AN:ANALYSIS_TYPE                 	MS
#MS
MS:INSTRUMENT_NAME               	Thermo TSQ Altis
MS:INSTRUMENT_TYPE               	Triple quadrupole
MS:MS_TYPE                       	ESI
MS:ION_MODE                      	POSITIVE
MS:MS_COMMENTS                   	Acylcarnitine (AcCa), ceramide, sphingomyelin (SM), phosphatidylcholine (PC),
MS:MS_COMMENTS                   	lysophosphatidylcholine (LPC), and lysophosphatidylethanolamine (LPE) species
MS:MS_COMMENTS                   	were identified as the [M+H]+ precursor ion, with product ion m/z values of 85.0
MS:MS_COMMENTS                   	for AcCa, 184.1 for PC, LPC and SM, 264.3 for ceramide and SM, and neutral loss
MS:MS_COMMENTS                   	of 141.0 for LPE. Diacylglycerol (DG) was detected as the [M+NH4]+ precursor
MS:MS_COMMENTS                   	ion, with product ions corresponding to neutral loss of 35.0 and RCOOH + NH3. PE
MS:MS_COMMENTS                   	was identified through neutral loss of the ethanolamine phosphate headgroup in
MS:MS_COMMENTS                   	positive ion mode (precursor m/z - 141) and a specific fatty acid product ion in
MS:MS_COMMENTS                   	negative ion mode. The PE species are listed under the negative ion mode data
MS:MS_COMMENTS                   	file.
#MS_METABOLITE_DATA
MS_METABOLITE_DATA:UNITS	pmoles/mg protein
MS_METABOLITE_DATA_START
Samples	4	5	3	1	6	2
Factors	Sample source:RKI1 cells | Factor:Control	Sample source:RKI1 cells | Factor:Control	Sample source:RKI1 cells | Factor:Control	Sample source:RKI1 cells | Factor:Drug Treated	Sample source:RKI1 cells | Factor:Drug Treated	Sample source:RKI1 cells | Factor:Drug Treated
Cer(d18:1/14:0)	6.47	4.12	4.78	1.08	0.88	1.13
Cer(d18:1/16:0)	202.62	154.02	162.71	11.26	13.99	21.83
Cer(d18:1/18:0)	181.71	163.72	175.37	9.13	11.15	23.73
Cer(d18:1/20:0)	15.89	13.03	11.64	1.72	1.39	2.77
Cer(d18:1/22:0)	27.67	15.09	19.55	4.36	3.96	6.01
Cer(d18:1/22:1)	10.00	12.05	7.40	0.99	0.90	2.05
Cer(d18:1/24:0)	83.09	25.62	61.47	24.31	11.38	31.99
Cer(d18:1/24:1)	486.55	337.87	372.95	51.05	38.59	77.06
Cholesterol	73874.3	94071.3	64227.5	42719.8	23681.1	28878.3
DG(32:0)	52.24	61.73	20.16	82.06	94.49	105.00
DG(32:1)	85.35	59.99	46.51	87.60	112.42	107.55
DG(34:0)	42.87	31.68	15.05	25.37	79.16	94.78
DG(34:1)	888.36	794.57	627.10	1027.84	1317.20	1428.82
DG(34:2)	321.19	522.47	247.22	556.96	1067.39	988.72
DG(36:0)	105.42	92.16	87.88	228.16	200.49	217.83
DG(36:1)	893.33	938.43	650.24	1415.39	1584.13	1626.59
DG(36:2)	1829.30	1982.63	1418.08	4237.24	3741.00	4461.36
DG(36:3)	696.08	794.89	453.91	1815.11	1827.38	2326.79
DG(36:4)	157.60	131.80	128.38	344.37	492.42	501.76
DG(36:5)	10.99	12.50	7.81	25.98	51.68	72.06
DG(38:3)	877.06	448.92	560.81	1606.45	660.54	742.79
DG(38:4)	415.59	433.14	165.56	909.67	828.08	1006.18
DG(38:5)	225.02	136.28	156.61	244.52	217.60	334.54
DG(38:6)	19.22	27.61	16.69	53.83	58.44	89.49
DG(40:4)	202.33	152.59	186.84	440.27	218.77	276.66
DG(40:5)	121.80	124.01	156.28	243.55	147.97	324.98
DG(40:6)	109.34	104.54	65.66	167.01	297.62	290.67
LPC(16:0)	175.467	99.668	136.120	111.398	82.060	158.216
LPC(16:1)	18.000	11.729	14.868	8.528	7.870	16.106
LPC(18:0)	23.205	13.251	18.674	62.003	39.609	69.941
LPC(18:1)	189.722	157.553	158.099	213.844	243.030	313.857
LPC(18:2)	13.280	18.238	11.853	80.265	54.991	111.307
LPC(20:3)	6.181	4.067	5.169	15.900	10.127	19.309
LPC(20:4)	5.867	3.346	4.359	5.049	3.804	7.013
LPC(22:4)	1.397	0.686	1.246	1.702	2.061	1.663
LPC(22:5)	4.629	2.297	4.178	1.890	1.815	2.789
LPC(22:6)	3.238	1.448	2.652	1.049	0.550	1.801
LPE(16:0)	108.930	81.702	72.608	65.350	93.705	90.618
LPE(16:1)	5.647	3.499	3.331	3.819	3.877	5.638
LPE(18:0)	240.518	104.045	158.123	261.018	191.136	361.005
LPE(18:1)	351.463	304.772	249.312	381.333	259.492	381.023
LPE(18:2)	14.277	20.008	12.126	94.164	131.455	115.711
LPE(20:3)	33.112	27.164	23.241	86.237	120.134	104.015
LPE(20:4)	50.901	31.439	25.785	47.531	63.109	58.385
LPE(22:4)	31.242	21.293	20.000	53.258	114.217	58.619
LPE(22:5)	89.644	51.042	58.865	60.440	112.098	93.338
LPE(22:6)	61.568	33.783	41.816	30.636	26.664	42.881
PC(32:0)	24265.8	34024.8	15859.9	12787.8	56250.4	54360.7
PC(32:1)	63789.2	79844.5	43413.6	24128.0	79075.5	85357.4
PC(34:0)	9395.5	8126.1	6281.5	3773.1	8555.7	9216.4
PC(34:1)	114781.7	158931.5	84580.8	72091.7	247995.1	237232.3
PC(34:2)	37309.9	65927.3	30357.5	36920.7	163757.9	152929.0
PC(36:0)	783.2	884.9	564.5	625.5	1770.9	1547.5
PC(36:1)	35724.3	44539.5	25287.4	47369.8	97331.8	98023.3
PC(36:2)	42928.7	66978.4	32608.1	73395.1	249401.4	229539.8
PC(36:3)	25585.0	47548.4	19486.6	51604.0	162566.0	146591.8
PC(36:4)	8825.4	20321.3	5768.1	10963.0	32220.5	42654.1
PC(36:5)	449.5	1284.7	253.4	2084.8	5827.2	5295.8
PC(38:4)	9143.7	14163.9	7019.3	17852.6	57261.3	47869.9
PC(38:5)	581.6	6645.1	9118.5	12606.0	31710.1	29684.4
PC(40:7)	814.0	1219.6	726.8	906.4	2008.1	2118.2
SM(36:2)	149.7	218.2	154.2	10.4	13.3	19.6
SM(40:2)	125.3	169.5	137.3	25.8	9.5	26.4
SM(42:2)	5230.6	4518.9	4509.7	297.4	129.5	262.1
SM(d18:1/14:0)	157.1	129.4	193.5	12.1	6.3	12.2
SM(d18:1/16:0)	3266.6	3779.4	3475.2	185.7	155.2	284.5
SM(d18:1/18:0)	1800.1	2996.0	2602.0	46.3	68.8	100.5
SM(d18:1/20:0)	6506.5	7771.0	5392.4	9753.7	14712.5	14877.5
SM(d18:1/22:0)	5674.3	6067.9	4554.9	13595.7	16317.5	17114.6
SM(d18:1/24:0)	642.0	546.6	516.5	7190.9	4318.1	4627.6
MS_METABOLITE_DATA_END
#METABOLITES
METABOLITES_START
metabolite_name	Ion	Precursor m/z	Product m/z
Cer(d18:1/14:0)	[M+H]	510.5	264.3
Cer(d18:1/16:0)	[M+H]	538.5	264.3
Cer(d18:1/18:0)	[M+H]	566.6	264.3
Cer(d18:1/20:0)	[M+H]	594.6	264.3
Cer(d18:1/22:0)	[M+H]	622.6	264.3
Cer(d18:1/22:1)	[M+H]	620.6	264.3
Cer(d18:1/24:0)	[M+H]	650.6	264.3
Cer(d18:1/24:1)	[M+H]	648.6	264.3
Cholesterol	[M-H2O+H]	369.4	161.1
DG(32:0)	[M+NH4]	586.5	551.5
DG(32:1)	[M+NH4]	584.5	549.5
DG(34:0)	[M+NH4]	614.6	579.5
DG(34:1)	[M+NH4]	612.6	577.5
DG(34:2)	[M+NH4]	610.5	575.5
DG(36:0)	[M+NH4]	642.6	607.6
DG(36:1)	[M+NH4]	640.6	605.6
DG(36:2)	[M+NH4]	638.6	603.5
DG(36:3)	[M+NH4]	636.6	601.5
DG(36:4)	[M+NH4]	634.5	599.5
DG(36:5)	[M+NH4]	632.5	597.5
DG(38:3)	[M+NH4]	664.6	629.6
DG(38:4)	[M+NH4]	662.6	627.5
DG(38:5)	[M+NH4]	660.6	625.5
DG(38:6)	[M+NH4]	658.5	623.5
DG(40:4)	[M+NH4]	690.6	655.6
DG(40:5)	[M+NH4]	688.6	653.6
DG(40:6)	[M+NH4]	686.6	651.5
LPC(16:0)	[M+H]	496.3	184.1
LPC(16:1)	[M+H]	494.3	184.1
LPC(18:0)	[M+H]	524.4	184.1
LPC(18:1)	[M+H]	522.4	184.1
LPC(18:2)	[M+H]	520.3	184.1
LPC(20:3)	[M+H]	546.4	184.1
LPC(20:4)	[M+H]	544.3	184.1
LPC(22:4)	[M+H]	572.4	184.1
LPC(22:5)	[M+H]	570.4	184.1
LPC(22:6)	[M+H]	568.3	184.1
LPE(16:0)	[M+H]	454.3	313.3
LPE(16:1)	[M+H]	452.3	311.3
LPE(18:0)	[M+H]	482.3	341.3
LPE(18:1)	[M+H]	480.3	339.3
LPE(18:2)	[M+H]	478.3	337.3
LPE(20:3)	[M+H]	504.3	363.3
LPE(20:4)	[M+H]	502.3	361.3
LPE(22:4)	[M+H]	530.3	389.3
LPE(22:5)	[M+H]	528.3	387.3
LPE(22:6)	[M+H]	526.3	385.3
PC(32:0)	[M+H]	734.6	184.1
PC(32:1)	[M+H]	732.6	184.1
PC(34:0)	[M+H]	762.6	184.1
PC(34:1)	[M+H]	760.6	184.1
PC(34:2)	[M+H]	758.6	184.1
PC(36:0)	[M+H]	790.6	184.1
PC(36:1)	[M+H]	788.6	184.1
PC(36:2)	[M+H]	786.6	184.1
PC(36:3)	[M+H]	784.6	184.1
PC(36:4)	[M+H]	782.6	184.1
PC(36:5)	[M+H]	780.6	184.1
PC(38:4)	[M+H]	810.6	184.1
PC(38:5)	[M+H]	808.6	184.1
PC(40:7)	[M+H]	832.6	184.1
SM(36:2)	[M+H]	729.6	184.1
SM(40:2)	[M+H]	785.7	184.1
SM(42:2)	[M+H]	813.7	184.1
SM(d18:1/14:0)	[M+H]	675.6	184.1
SM(d18:1/16:0)	[M+H]	703.6	184.1
SM(d18:1/18:0)	[M+H]	731.6	184.1
SM(d18:1/20:0)	[M+H]	759.6	184.1
SM(d18:1/22:0)	[M+H]	787.7	184.1
SM(d18:1/24:0)	[M+H]	815.7	184.1
METABOLITES_END
#END